TD Cowen raised the firm’s price target on Establishment Labs to $60 from $50 and keeps an Outperform rating on the shares. The firm met with management who revealed that the company is continuing to move closer to Motiva’s FDA approval. Management expects to receive a GMP inspection date “very soon” and is also engaged in labeling discussions with the agency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ESTA:
- New Regulation Risk for Establishment Labs Holdings – What’s the Latest?
- Establishment Labs price target raised to $49 from $32 at Citi
- Establishment Labs price target raised to $53 from $45 at BTIG
- Establishment Labs reports Q4 EPS (79c), consensus (91c)
- Is ESTA a Buy, Before Earnings?
Questions or Comments about the article? Write to editor@tipranks.com